PHRR220921-004972
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (CONNEX-1)
Boehringer Ingelheim (Philippines), Inc.·Phase 3·Philippine Health Research RegistrySuspended
Study focus
- Disease/Condition
- Schizophrenia
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Boehringer Ingelheim (Philippines), Inc.
- Funder
- Boehringer Ingelheim Korea Ltd
- Location
- Australia Brazil Canada China Colombia Germany Greece Italy Japan Mexico New Zealand Norway Philippi
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Dec 06, 2022
- End date
- N/A
ICD-10 classifications
SchizophreniaSimple schizophreniaSchizophrenia, unspecifiedOther schizophreniaParanoid schizophrenia
Data source
- Registry
- Philippine Health Research Registry
- Trial ID
- PHRR220921-004972
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for PHRR220921-004972 through Pure Global AI's free database. This Phase 3 trial is sponsored by Boehringer Ingelheim (Philippines), Inc. and is currently Suspended. The study focuses on Schizophrenia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.